One Year Experience with Lutetium-DOTATATE for Disseminated NETs in the Gregorio Marañon Hospital

#2120

Introduction: The main curative therapy for NET is surgical resection when the disease is localized. But high percentage of patients is diagnosed with advanced disseminated disease and the peptide receptor radionuclide therapy (PRRT) with somatostatin analogs (SSA) is an emerging effective treatment.

Aim(s): Evaluate short term effectiveness and tolerability of 177-Lutetium-DOTATATE in the metastatic or inoperable NETs in our centre.

Materials and methods: Analyse bichemical, clinical and imaging response and side effects of the therapy.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Picallo P

Authors: Picallo M, Percovich J, García Centeno R, Rotger A, Colon A,

Keywords: Neuroendocrine, Lutetium, Radionuclide therapy,

To read the full abstract, please log into your ENETS Member account.